Kainomyx
Kainomyx is a pre-revenue biotechnology company developing small-molecule therapeutics that target cytoskeletal proteins of parasites for malaria and other neglected tropical diseases, applying its cytoskeleton platform across human, veterinary, and agricultural health via pharmaceutical partnerships.
- Company typePrivate
- Founded2019
- HeadquartersPalo Alto, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Kainomyx does
Kainomyx is a privately held, pre-revenue biotechnology company founded in 2019 and headquartered in Mountain View, California, with a wholly-owned Indian R&D subsidiary (Kainomyx Research Laboratories India Pvt. Ltd.) launched in August 2024 at the C-CAMP incubator in Bangalore. The company is built around a proprietary cytoskeleton platform technology that combines deep expertise in cytoskeletal biology with biochemical and biophysical approaches to discover small-molecule therapeutics targeting cytoskeletal proteins of parasites. This mechanism of action is positioned as novel for anti-malarial and anti-parasitic drug discovery, addressing well-documented unmet needs including drug resistance and limited treatment options for neglected tropical diseases.
Kainomyx's product surface comprises a cytoskeleton-based drug discovery platform, a malaria therapeutics program, parasitic disease diagnostics aimed at identifying asymptomatic carriers, and an anti-malarial co-development program with Dr. Reddy's Laboratories and Aurigene Pharmaceutical Services (August 2024 non-binding MoU), with a more recent collaboration with Calibr-Skaggs announced in February 2026. The company applies a One Health framework spanning human, veterinary, and agricultural applications. Revenue is not yet generated; the stated future revenue model is licensing royalties and commercialization economics from pharmaceutical partners, with commercialization planned for the U.S., Europe, and low- and middle-income countries. Go-to-market is partnership-driven via CRDMO collaborators rather than direct sales, supported by a small founding and board team (James Spudich as Executive Chairman; co-founders Annamma Spudich, Suman Nag, Darshan Trivedi, and Kathleen Ruppel; additional directors including William J. Rutter, Chris Sommerville, Heather Youngs, Dirk Thye MD, and Amit L. Mehta).
Kainomyx firmographics
Firmographics- Name
- Kainomyx
- Legal name
- Kainomyx, Inc.
- Website
- https://kainomyx.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Kainomyx is a pre-revenue biotechnology company developing small-molecule therapeutics that target cytoskeletal proteins of parasites for malaria and other neglected tropical diseases, applying its cytoskeleton platform across human, veterinary, and agricultural health via pharmaceutical partnerships.
- Ownership category
- akta.pro rank
Kainomyx industry classification
Industry- Product category
- Biotechnology / Anti-Parasitic Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where Kainomyx is headquartered
LocationHeadquarters
- HQ city
- Palo Alto
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Kainomyx business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Drug Development and Commercialization: Pre-revenue biotechnology company focused on developing and commercializing novel therapeutics. Revenue will be generated through drug commercialization, licensing agreements, and potential partnerships for co-development and commercialization of anti-malarial and anti-parasitic drugs.
- Malaria Therapeutics Program: Development of malaria therapeutics as core focus area, with funding supporting advancement of the therapeutics program and programs in malaria diagnosis and therapeutics in other parasitic diseases.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels3 records
Kainomyx product offering
Product offeringCore offering
Kainomyx is a pre-revenue biotechnology platform company that uses a proprietary cytoskeleton-based drug discovery platform to develop small-molecule therapeutics and diagnostic tests targeting cytoskeletal proteins of parasites. The company addresses malaria and other neglected tropical diseases across human, veterinary, and agricultural applications, advancing candidates through strategic CRDMO partnerships with established pharmaceutical companies.
Product overview
Kainomyx is a platform company that has developed a proprietary cytoskeleton platform technology for small molecule drug discovery. The company operates programs in malaria therapeutics, parasitic disease diagnostics, and anti-malarial drug development. Its cytoskeleton platform enables targeting of cytoskeletal proteins in parasites, representing a novel mechanism of action. The company also offers tests to identify asymptomatic carriers for disease control. Through partnerships with Dr. Reddy's Laboratories and Aurigene Pharmaceutical Services, Kainomyx is advancing affordable anti-malarial drugs globally.
Differentiator
Problem solved
Functional benefit
Products and services
- Malaria Therapeutics Program
Quantifiable outcome
- Top 5 ranking out of 139 global startups tackling malaria
Companies that use Kainomyx
Customer profileSegments3 records
Ideal customer profiles1 record
Kainomyx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Kainomyx partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered supporting and core.
- Calibr-SkaggssupportingCalibr-Skaggs and Kainomyx joined forces to accelerate development of antimalarial drugs, according to news-medical report. Details of the collaboration scope and structure are limited in the available source.
- Dr. Reddy's Laboratories / Aurigene Pharmaceutical ServicescoreDr. Reddy's Laboratories and its CRDMO arm Aurigene Pharmaceutical Services signed a non-binding Memorandum of Understanding with Kainomyx for the development and commercialization of affordable anti-malarial drug. The partnership targets the U.S., Europe, and low and middle-income countries. The MoU is subject to signing of a definitive agreement. Kainomyx contributes its proprietary cytoskeletal protein targeting platform with novel mechanism of action for anti-malarial drug development.
- C-CAMP (Centre for Cellular and Molecular Platforms)supportingKainomyx Research Laboratories India Pvt. Ltd., a wholly-owned subsidiary of Kainomyx Inc., launched in India at the C-CAMP incubator located on the campus of National Center for Biological Sciences (NCBS), Bangalore. C-CAMP provides incubator support and ecosystem for biotech startups in India.
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
Kainomyx competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key highlights7 records
Customer concentration
Kainomyx social profiles
Digital presenceKainomyx financial estimates
Financial estimateRevenue estimate
Valuation estimate
Kainomyx leadership team
Management profileNumber of profiles
Profiles15 records
Kainomyx subsidiaries and ownership
Company hierarchySubsidiaries1 record
Kainomyx funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Kainomyx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Kainomyx
What does Kainomyx do?
Kainomyx is a pre-revenue biotechnology platform company that uses a proprietary cytoskeleton-based drug discovery platform to develop small-molecule therapeutics and diagnostic tests targeting cytoskeletal proteins of parasites. The company addresses malaria and other neglected tropical diseases across human, veterinary, and agricultural applications, advancing candidates through strategic CRDMO partnerships with established pharmaceutical companies.
Is Kainomyx a public or private company?
Kainomyx is a private company. It is classified as venture growth investor backed and is currently operating.
When was Kainomyx founded?
Kainomyx was founded in 2019. It employs 1 to 10 people.
Where is Kainomyx based?
Kainomyx is headquartered in Palo Alto, United States, in the North America region.
How does Kainomyx make money?
Two revenue lines are on record. Drug Development and Commercialization is the primary driver. The others are malaria Therapeutics Program.
Does Kainomyx have an API?
No public API is recorded for Kainomyx.
What industry is Kainomyx in?
Kainomyx's product category is Biotechnology / Anti-Parasitic Therapeutics. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2834.